azd1332

**AZD1332** is a potent, selective, and orally bioavailable **small molecule inhibitor** targeting neurotrophic tyrosine kinase receptors **TrkA, TrkB, and TrkC** (also known as neurotrophic tyrosine kinase, receptor, type 1, 2, and 3)[1][3][5]. It competitively inhibits the ATP-binding site of these receptors with low nanomolar IC50 values, leading to blockade of downstream signaling related to neuronal growth, survival, and oncogenic transformation[1][5]. Developed for research in oncology and neurobiology, AZD1332 is not approved for human use and is primarily used for preclinical studies. Notably, it has been investigated by AstraZeneca for its effects in pancreatic cancer and head and neck cancer models[2][7]. Mechanistically, AZD1332 disrupts ligand-induced activation and phosphorylation of Trk receptors, thereby modulating cell survival and growth pathways[1][5].

Other names

AZD1332AZD-1332AZD 1332AZ-23 racemateAZ23 racemateAZ 23 racemateAZ-23 compoundAZ23 compoundAZ 23 compound5-chloro-2-N-[1-(5-fluoropyridin-2-yl)ethyl]-4-N-(3-propan-2-yloxy-1H-pyrazol-5-yl)pyrimidine-2,4-diamine